Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis | Zendy

Catherine Shelton | Zendy; Matthew B. McNeil | Zendy; R. H. Allen | Zendy; Lindsay Flint | Zendy; Dara Russell | Zendy; Bryan J. Berube | Zendy; Aaron Korkegian | Zendy; Yulia Ovechkina | Zendy; Tanya Parish | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis

Author(s) -

Catherine Shelton,

Matthew B. McNeil,

R. H. Allen,

Lindsay Flint,

Dara Russell,

Bryan J. Berube,

Aaron Korkegian,

Yulia Ovechkina,

Tanya Parish

Publication year - 2022

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02041-21

Subject(s) - intracellular , mycobacterium tuberculosis , cytochrome c oxidase , mutant , microbiology and biotechnology , biology , oxidase test , cytochrome , bacteria , strain (injury) , mitochondrion , protein subunit , respiration , cellular respiration , electron transport complex iv , biochemistry , tuberculosis , enzyme , gene , genetics , medicine , botany , pathology , anatomy

We previously identified a series of triazolopyrimidines with antitubercular activity. We determined thatMycobacterium tuberculosis strains with mutations in QcrB, a subunit of the cytochromebcc-aa3 supercomplex, were resistant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research